Company Description
International Isotopes Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, and radiopharmaceutical and radiochemical contract manufacturing services in the United States and internationally.
It operates through four segments: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, and Fluorine Products.
The Nuclear Medicine Standards segment manufactures sources and standards associated with single photon emission computed and positron emission tomography imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry.
This segment also offers flood sources, dose calibrators, rod sources, flexible and rigid rulers, spot and pen point markers, and various specialty design items.
The Cobalt Products segment produces bulk cobalt; fabricates cobalt capsules for radiation therapy and various industrial applications; and recycles expended cobalt sources.
The Radiochemical Products segment produces and distributes various isotopically pure radiochemicals and sodium iodide I-131 generic drug product for medical, industrial, and research applications.
The Fluorine Products segment is involved in the production of small-scale qualification samples of high purity fluoride gas for various industrial applications, as well as development of laboratory and analytical processes required to support the planned uranium de-conversion and fluorine extraction facility.
The company sells its products directly to end users and distributors. International Isotopes Inc. was incorporated in 1995 and is headquartered in Idaho Falls, Idaho.
| Country | Indonesia |
| Founded | 1995 |
| IPO Date | Aug 14, 1997 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 39 |
| CEO | Shahe Bagerdjian |
Contact Details
Address: 4137 Commerce Circle Idaho Falls, Idaho 83401 United States | |
| Phone | 2085245300 |
| Website | intisoid.com |
Stock Details
| Ticker Symbol | INIS |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001038277 |
| CUSIP Number | 45972C102 |
| ISIN Number | US45972C1027 |
| Employer ID | 74-2763837 |
| SIC Code | 3823 |
Key Executives
| Name | Position |
|---|---|
| W. Matthew Cox B.S., CPA | Chief Financial Officer and Secretary |
| Shahe Bagerdjian | President,Chief Executive Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 29, 2024 | 10-K | Annual Report |
| Feb 8, 2024 | 8-K | Current Report |
| Nov 13, 2023 | 10-Q | Quarterly Report |
| Aug 11, 2023 | 10-Q | Quarterly Report |
| Jul 18, 2023 | 8-K | Current Report |
| May 24, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 24, 2023 | DEF 14A | Other definitive proxy statements |
| May 15, 2023 | 10-Q | Quarterly Report |
| May 10, 2023 | 8-K | Current Report |
| May 3, 2023 | 10-K/A | [Amend] Annual report |